Quoin Pharmaceuticals Director Anthony Culverwell Buys Stock

What Happened
Anthony James Culverwell, a director of Quoin Pharmaceuticals, purchased 6,146 American Depositary Shares (ADSs) on 2026-08-31 at $4.88 per ADS for a total cash outlay of $29,992. In the same private placement he received 3,073 accompanying warrants (reported as a derivative), issued at the same combined purchase price and representing 50% warrant coverage.

Key Details

• Transaction date: August 31, 2026; Form 4 filed September 1, 2026 (period of report 2026-08-31). Filing appears timely.
• Purchase: 6,146 ADSs at $4.88 each = $29,992 total.
• Derivative: 3,073 warrants issued (no per-instrument price listed separately; part of combined $4.88 purchase price).
• ADS conversion: Each ADS represents 35 ordinary shares — the 6,146 ADSs equal 215,110 underlying ordinary shares; the 3,073 warrants would represent 107,555 ordinary shares if exercised (subject to terms).
• Warrant terms: exercisable immediately upon issuance subject to a beneficial ownership cap; expire the earlier of five years from issuance or 30 days after public announcement that the primary endpoint was met in clinical trial CL-QRX003-004 for Netherton Syndrome.
• Transaction type codes: P = Purchase (ADSs), derivative reported for warrants. No indication of tax withholding, 10b5-1 plan, or late filing flag.

Context
This was a private placement purchase (issuer offering) with 50% warrant coverage — a purchase is generally viewed as a direct acquisition of company exposure rather than a sale. The warrants give the holder the right to buy additional ADSs (subject to the ownership cap and expiry conditions), including a clause that shortens expiry if a key clinical trial endpoint is announced met. As always, this disclosure is factual reporting of insider activity and not a recommendation.